The cytotoxicity of a conjugate composed of human epidermal growth factor and eosinophil cationic protein

Anticancer Research

Volumn 22, Issue 6 C, 2002, Pages 4141-4145

  Jinno, Hiromitsu ^a   Ueda, Masakazu ^a   Ozawa, Soji ^a   Ikeda, Tadashi ^a   Kitajima, Masaki ^a   Maeda, Takashi ^b   Seno, Niasaharu ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Breast cancer; Conjugate; Eosinophil cationic protein; Epidermal growth factor

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA UROGASTRONE; IMMUNOTOXIN;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; IMMUNOGENICITY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

BLOOD PROTEINS; BREAST NEOPLASMS; CARCINOMA, SMALL CELL; DISULFIDES; EOSINOPHIL GRANULE PROTEINS; EPIDERMAL GROWTH FACTOR; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; RIBONUCLEASES; TUMOR CELLS, CULTURED;

EID: 0036875373     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ozawa S, Ueda M, Ando N, Shimizu N and Abe O: Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 63: 2169-2173, 1989.
2. Sainsbury JRC, Frandon JR, Needham GK, Malcolm AJ and Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1: 1398-1402, 1987.
3. Hirota N, Ueda M, Ozawa S, Abe O and Shimizu N: Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Res 49: 7106-7109, 1989.
4. Osaku M, Ueda M, Ando N, Shinozawa Y, Hirota N, Shimizu N and Abe O: Targeted killing of squamous carcinoma cells by a monoclonal antibody-Pepleomycin conjugate which recognizes the EGF receptor. Anticancer Res 11: 1951-1956, 1991.
5. Soler-Rodriguez AM, Ghetie MA, Oppenheimer-Marks N, Uhr JW and Vitetta ES: Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp Cell Res 206: 227-234, 1993.
6. Pai LH, Bookman MA, Ozols RF, Young RC, Smith JW, Longo DL, Gould B, Frankel A, McClay EF, Howell S, Reed E, Willingham MC, FitzGerald DJ and Pastan I: Clinical evaluation of intraperitoneal pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 9: 2095-2103, 1991.
7. Vallera DA, Panoskaltsis-Mortari A and Blazar BR: Renal dysfunction accounts for the dose limiting toxicity of DT390anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin. Protein Eng 10: 1071-1076, 1997.
8. Futami J, Seno M, Ueda M, Tada H and Yamada H: Inhibition of cell growth by a fused protein of human ribonuclease 1 and human basic fibroblast growth factor. Protein Eng 12: 1013-1019, 1999.
9. Psarras K, Ueda M, Yamamura T, Ozawa S, Kitajima M, Aiso S, Komatsu S and Seno M: Human pancreatic RNase1-human epidermal growth factor fusion: an entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas. Protein Eng 11: 1285-1292, 1998.
10. Psarras K, Ueda M, Tanabe M, Kitajima M, Aiso S, Komatsu S and Seno M: Targeting activated lymphocytes with an entirely human immunotoxin analogue: human pancreatic RNase1-human IL-2 fusion. Cytokine 12: 786-790, 2000.
11. Jinno H, Ueda M, Ozawa S, Kikuchi K, Ikeda T, Enomoto K and Kitajima M: Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines -a trial for less immunogenic chimeric toxin-. Cancer Chemother Pharmacol 38: 303-308, 1996.
12. Futami J, Seno M, Kosaka M, Tada H, Seno S and Yamada H: Recombinant human pancreatic ribonuclease produced in E coli: importance of the amino-terminal sequence. Biochem Biophys Res Commun 216: 406-413, 1995.
13. Jinno H, Ueda M, Ozawa S, Ikeda T, Enomoto K, Psarras K, Kitajima M, Yamada H and Seno M: Epidermal growth factor receptor-dependent cytotoxicity for human squamous carcinoma cell lines of a conjugate composed of human EGF and RNase 1. Life Sci 58: 1901-1908, 1996.
14. Gleich GJ, Loegering DA, Bell MP, Checkle JL, Ackerman SJ and Mckean DJ: Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci USA 83: 3146-3150, 1986.
15. Motojima S, Frigas E, Loegering DA and Gleich GJ: Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis 139: 801-805, 1989.
16. McLaren DJ, Peterson CG and Venge P: Schistosoma mansoni: further studies of the interaction between schictosomula and glanulocyte-derived cationic protein in vitro. Parasitology 88: 491-503 1984.
17. Lehler RI, Szklarek D, Barton A, Ganz T, Hamann KJ and Gleich GJ: Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol 142: 4428-4434, 1989.
18. Mallorqui-Fernandez G, Pous J, Peracula R, Aymami J, Maeda T, Tada H, Yamada H, Seno M, de Llorens R, Gomis-Ruth FX and Coll M: Three-dimensional crystal structure of human eosinophil cationic protein (RNase 3) at 1.75 Å resolution. J Mol Biol 300: 1297-1307, 2000.
19. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr JW and Thorpe PE: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51: 4052-4058, 1991.
20. Tepler I, Schwartz G, Parker K, Charette J, Kadin ME, Woodworth TG and Schnipper LE: Phase 1 trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 73: 1276-1285, 1994.
21. Pastan IH and Willingham MC: Receptor-mediated endocytosis of hormones in cultued cells. Annu Rev Physiol 43: 239-250, 1981.
22. Maeda T, Kitazoe M, Tada H, de Llorens R, Salomom DS, Ueda M, Yamada H and Seno M: Growth inhibition of mammalian cells by eosinophil cationic protein. Eur J Biochem 269: 307-316, 2002.
23. Ozawa S, Ueda M, Ando N, Abe O and Shimizu N: High incidence of EGF receptor hyperproduction in esophageal squamous-cell carcinomas. Int J Cancer 39: 333-337, 1987.
24. Peterson H: Organization of the vascular structure in tumors. In: Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors (Peterson H eds). Boca Raton, FL, CRC press, 1979, pp31-39.
25. Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, Iihara K, Doki Y, Hirano S, Takeichi M and Mori T: Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 139: 17-23, 1991.
26. Brinkmann U and Pastan I: Immunotoxins against cancer. Biochim Biophys Acta 1198: 27-45, 1994.